The ability of σ2R drugs to inhibit tumor cell proliferation through mechanisms that may involve apoptosis, intracellular Ca2+ and sphingolipids have been investigated, and such findings may lead to the development of σ drugs as cancer therapeutic agents. This evidence concerns the gene TMEM97 and cancer.